Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mucus hypersecretion in chronic obstructive pulmonary disease.

D F Rogers1

  • 1Department of Thoracic Medicine, National Heart & Lung Institute (Imperial College), Dovehouse Street, London SW3 6LY, UK.

Novartis Foundation Symposium
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of airway mucin gene expression.

Methods in molecular medicine·2011
Same author

Intravenously administered oligonucleotides can be delivered to conducting airway epithelium via the bronchial circulation.

Gene therapy·2006
Same author

Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics.

Neurotoxicity research·2006
Same author

Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma.

Respiratory medicine·2005
Same author

Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD.

Thorax·2003
Same author

Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease.

Expert opinion on pharmacotherapy·2001

Airway mucus hypersecretion is common in chronic obstructive pulmonary disease (COPD), contributing to symptoms and exacerbations. Further research is needed to develop effective mucus-inhibiting drugs for COPD patients.

Area of Science:

  • Pulmonary Medicine
  • Respiratory Physiology

Background:

  • Airway mucus hypersecretion is a hallmark of chronic obstructive pulmonary disease (COPD), presenting as sputum production and glandular changes.
  • Clinical consequences include impaired gas exchange, reduced mucociliary clearance, and increased susceptibility to bacterial infections and exacerbations.
  • The precise role of mucus in COPD pathophysiology remains debated, with early studies suggesting independence from airflow obstruction, while later research indicates a link to disease progression.

Purpose of the Study:

  • To review the contribution of mucus hypersecretion to COPD pathophysiology.
  • To highlight the need for developing drugs that inhibit mucus hypersecretion in specific COPD patient groups.
  • To emphasize the importance of future research in understanding intrinsic mucus abnormalities in COPD for targeted therapeutic development.

Related Experiment Videos

Main Methods:

  • Literature review of epidemiological studies and clinical research on mucus hypersecretion in COPD.
  • Analysis of the association between mucus production and COPD outcomes like lung function decline, hospitalization, and mortality.
  • Evaluation of the current status and challenges in clinical studies of mucoactive drugs for COPD.

Main Results:

  • Mucus hypersecretion is prevalent in COPD and linked to impaired lung function, increased hospitalizations, and mortality in certain patient cohorts.
  • Despite its contribution to morbidity, mucoactive drugs are not routinely recommended due to ambiguity in clinical trial data.
  • There is a clear need to investigate intrinsic mucus abnormalities in COPD to guide the development of targeted mucolytic therapies.

Conclusions:

  • Mucus hypersecretion significantly impacts COPD morbidity and mortality in specific patient populations.
  • Development of effective mucus inhibitors is crucial for managing COPD.
  • Future research focusing on the intrinsic properties of COPD mucus is essential for advancing therapeutic strategies.